
    
      Patients are randomized to receive oral atovaquone at 1 of 2 doses once daily or aerosolized
      pentamidine once every 4 weeks. Treatment continues until 18 months after the last patient is
      enrolled. Patients are stratified into primary or secondary prophylaxis strata based on prior
      occurrence of a PCP episode.
    
  